---
url: https://www.servicesaustralia.gov.au/lymphoma-refractory-follicular-b-cell-non-hodgkins-lymphoma
title: Lymphoma - refractory follicular B-cell non-Hodgkin’s lymphoma - Health professionals - Services AustraliaServices AustraliaServices Australia
scrapedAt: 2026-02-20T21:41:12.299Z
source: servicesaustralia.gov.au
---
# Lymphoma - refractory follicular B-cell non-Hodgkin’s lymphoma

The Pharmaceutical Benefits Scheme (PBS) subsidises idelalisib for patients with refractory follicular B-cell non-Hodgkin’s lymphoma.

## on this page

-   [Patient eligibility](#a1)
-   [Authority applications](#a2)
-   [More information](#a3)

## Patient eligibility

The PBS subsidises treatment with idelalisib under the _National Health Act 1953_, section 85 for patients with refractory follicular B-cell non-Hodgkin’s lymphoma.

Patients must be eligible for the [PBS](/pharmaceutical-benefits-scheme) and meet relevant restriction criteria.

The [Schedule of Pharmaceutical Benefits](http://www.pbs.gov.au/pbs/home;jsessionid=jrrab7f28xtjycras12yiccu) on the [PBS website](http://www.pbs.gov.au/pbs/home) outlines restrictions for prescribing idelalisib.

## Authority applications

### Applying for initial treatment

To apply for initial authority approval to prescribe PBS-subsidised idelalisib to treat refractory follicular B-cell non-Hodgkin’s either:

-   use the [Online PBS Authorities in HPOS](/apply-for-pbs-authority?context=20)
-   call the [PBS authority approvals line](/health-professionals-contact-information?context=20#pbsauthority).

### Applying for continuing treatment

Continuing PBS-subsidised treatment with idelalisib is Authority Required (Streamlined). It doesn’t need prior authority approval from us for listed quantities and repeats.

## More information

Call the [PBS authority approvals](/health-professionals-contact-information?context=20#pbsauthority) line for further information.
